Oxazaphosphorine alkylators & the proximal tubule
Ifosfamide Fanconi syndrome
Mesna guards the bladder, but nothing guards the proximal tubule — ifosfamide's chloroacetaldehyde metabolite is made inside the tubular cell itself, draining its energy and its reabsorptive machinery until phosphate, glucose, bicarbonate, and amino acids leak into the urine.
- 4%
- Fanconi-like syndromeIncidence of overt Fanconi-like syndrome with high-dose ifosfamide in a prospective children/young-adult cohort — while acute subclinical tubular changes were seen in every patientPMID 8625085
- 100 g/m²
- cumulative-dose ceilingIn Skinner's landmark cohort total ifosfamide dose was the only independent risk factor; cumulative doses ≥100 g/m² should be avoided in childrenPMID 8774570
- 45%
- reduced GFRGlomerular filtration rate below normal (61–85 mL/min/1.73m²) in 10 of 22 evaluable children after ifosfamidePMID 8774570
- 70×
- β2-microglobulinuriaMedian rise in urinary β2-microglobulin after a single 5-day ifosfamide cycle — the low-molecular-weight proteinuria that flags proximal tubular injury and predicted chronic damagePMID 8625085
- despite mesna
- no tubular protectionTubular enzymuria and proteinuria rose in every patient given ifosfamide with mesna — mesna prevents hemorrhagic cystitis, not proximal tubular toxicityPMID 2879626
Teaching case · illustrative composite, not a real patient
A 4-year-old girl finishing ifosfamide-based therapy for a rhabdomyosarcoma (cumulative dose approaching 90 g/m²) is noted on routine labs to have a serum phosphate of 2.1 mg/dL, bicarbonate 17 mmol/L, and 1+ glucose on urinalysis despite a normal blood glucose. Her growth has plateaued and she has started to bow at the knees.
Work-up shows a low tubular reabsorption of phosphate, a normal-anion-gap metabolic acidosis with inappropriately alkaline urine (proximal, type 2 renal tubular acidosis), glycosuria with euglycemia, generalized aminoaciduria, and elevated urinary β2-microglobulin — the full proximal-tubule (Fanconi) picture. Serum creatinine is only mildly elevated. Ifosfamide is not re-dosed; she is started on oral phosphate, alkali, and calcitriol replacement with close monitoring of growth and bone health. Over the following year the acidosis and phosphate wasting partially improve but do not fully resolve.
Teaching point — Ifosfamide injures the proximal tubule before the glomerulus: the syndrome to recognize is hypophosphatemia with phosphaturia, proximal (type 2) RTA, glycosuria with normal blood glucose, and low-molecular-weight proteinuria — in a young child on a high cumulative ifosfamide dose. It can present as hypophosphatemic rickets and growth failure, may be permanent, and mesna does not prevent it. Management is supportive electrolyte/alkali replacement and avoiding further high cumulative dosing.
How it happens
The pathophysiology as a cascade — select a step to follow the mechanism.
Proximal tubular cells express CYP3A and CYP2B and oxidize ifosfamide in situ to the nephrotoxic metabolite chloroacetaldehyde (CAA) — the injury is generated inside the target cell, not merely delivered to it.
PMID 16049550 (opens PubMed in a new tab)CAA depletes intracellular glutathione and ATP; glutathione-depleted tubular cells show dose-dependent damage, marking redox and energy collapse as central to the injury.
PMID 16049550 (opens PubMed in a new tab)CAA inhibits the tubular Na+/Ca2+ exchanger, raising intracellular free calcium and driving necrotic (rather than apoptotic) proximal tubular cell death.
PMID 16221203 (opens PubMed in a new tab)CAA inhibits proximal endocytosis and the vacuolar H+-ATPase and lowers ATP, crippling the receptor-mediated uptake and pumps the proximal tubule needs to reclaim filtrate — the direct cause of the Fanconi leak.
PMID 18214444 (opens PubMed in a new tab)The result is simultaneous urinary loss of phosphate, glucose, bicarbonate, amino acids, and low-molecular-weight proteins — clinically hypophosphatemia, proximal RTA, glycosuria with euglycemia, aminoaciduria, and β2-microglobulinuria.
PMID 8625085 (opens PubMed in a new tab)
How we learned it
- 1987
Goren and colleagues document tubular enzymuria and proteinuria in every one of 16 patients given ifosfamide with mesna, with a time course indicating tubular cell necrosis.
Established early that mesna — which prevents hemorrhagic cystitis — does not protect the proximal tubule, so tubular toxicity is a distinct, unguarded problem.
PMID 2879626 (opens PubMed in a new tab) - 1995
Ho et al. prospectively characterize acute ifosfamide nephrotoxicity in children and young adults, finding subclinical tubular changes in all patients and a 4% incidence of overt Fanconi-like syndrome, with severe β2-microglobulinuria predicting chronic damage.
Separated the near-universal acute, reversible tubular leak from the smaller subset who progress to chronic Fanconi syndrome, and named a laboratory predictor.
PMID 8625085 (opens PubMed in a new tab) - 1996
Skinner et al. (Lancet) study 23 children and identify total ifosfamide dose as the only independent risk factor for chronic proximal tubular toxicity, with subnormal GFR in 45% and hypophosphatemic rickets or RTA in six.
The landmark risk-factor analysis: cumulative dose drives chronic nephrotoxicity, and doses ≥100 g/m² should be avoided in children.
PMID 8774570 (opens PubMed in a new tab) - 1998
Loebstein and Koren critically review the predictive risk factors, concluding cumulative dose ≥60 g/m² is the most consistent predictor and age <5 years the strongest patient factor for severe chronic tubulopathy.
Consolidated cumulative dose and young age as the dominant, actionable risk factors a clinician can weigh at prescription.
PMID 9606250 (opens PubMed in a new tab) - 2005
Benesic et al. show chloroacetaldehyde inhibits the Na+/Ca2+ exchanger in human proximal tubule cells, and Aleksa et al. demonstrate proximal tubular cells themselves metabolize ifosfamide to chloroacetaldehyde.
Localized the injury: the toxic metabolite is generated inside the proximal tubule, and disturbed calcium handling and energy failure follow.
PMID 16221203 (opens PubMed in a new tab) - 2009
Oberlin et al. report ~10-year renal outcomes in 183 children: most retain normal tubular and glomerular function, but a reduced tubular phosphate threshold persists in 24% and toxicity can be permanent and progress over time.
Defined the long-term prognosis at moderate doses — mostly favorable, but with a persistent tubular signature that requires lifelong surveillance.
PMID 19826134 (opens PubMed in a new tab)
The landmark studies
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna
Goren MP, et al. · Cancer Treat Rep 1987 · PMID 2879626
Urinary tubular enzymes and protein rose in every patient given ifosfamide with mesna, with a time course indicating tubular cell necrosis — mesna prevents cystitis, not tubular injury.
16/16 patients with tubular enzymuria despite mesna 1.2 g/m²/day
A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults
Ho PT, et al. · Cancer 1995 · PMID 8625085
Acute subclinical tubular dysfunction occurred in all patients; 4% developed a Fanconi-like syndrome, and severe β2-microglobulinuria predicted chronic nephrotoxicity.
4% Fanconi-like syndrome; β2-microglobulin ↑70-fold (0.02→1.42 mg/mmol); aminoaciduria 21/23; phosphate threshold 1.22→0.82 mmol/L
Risk factors for ifosfamide nephrotoxicity in children
Skinner R, et al. · Lancet 1996 · PMID 8774570
Total ifosfamide dose was the only independent risk factor for chronic proximal tubular toxicity; GFR was subnormal in 45% and six children had hypophosphatemic rickets or RTA.
Median dose 100.8 g/m²; GFR low in 10/22 (45%); moderate/severe toxicity in 6/10 given >100 g/m² vs 2/10 below
Long-term evaluation of ifosfamide-related nephrotoxicity in children
Oberlin O, et al. · J Clin Oncol 2009 · PMID 19826134
At moderate cumulative doses renal toxicity was moderate overall, but a reduced tubular phosphate threshold persisted in a quarter of survivors and could be permanent and progressive.
89.5% normal tubular function and 78.5% normal GFR at a median 10-year follow-up; phosphate threshold reduced in 24% (grade 1 in 15%, grade 2 in 8%); glycosuria detected in 37% but >0.5 g/24 h in only 5%; median dose 54 g/m² (range 18–117)
What the data says now
How disproportionately each agent's FAERS reports name these phenotypes vs. all other drugs (reporting odds ratio; significant signals only, 95% CI lower bound > 1; as of 2026-09-01). A reporting signal, not incidence or proven causation. A dash means tested without reaching significance, not a phenotype that never occurs — ATN and AIN undercount badly, most true cases filing as generic “acute kidney injury”. Computed by this atlas on the current snapshot — a published disproportionality analysis will not match cell for cell (different window, different term set).
| Agent | FANC | LYTE | ATN |
|---|---|---|---|
| Ifosfamide | Ifosfamide, Fanconi Syndrome: ROR 34.96, 175 reports | Ifosfamide, Electrolyte Disturbance: ROR 2.67, 512 reports | Ifosfamide, Acute Tubular Necrosis: ROR 2.80, 28 reports |
Overt Fanconi-like syndrome
Children/young adults on high-dose ifosfamide (prospective cohort)
PMID 8625085 (opens PubMed in a new tab)Subnormal GFR after ifosfamide
Children at a median ~100 g/m² cumulative dose (Skinner cohort)
PMID 8774570 (opens PubMed in a new tab)Persistently reduced tubular phosphate threshold
183 children at ~10-year follow-up (moderate doses)
PMID 19826134 (opens PubMed in a new tab)Most consistent risk factor
Critical review of pediatric predictive risk factors
PMID 9606250 (opens PubMed in a new tab)Strongest patient risk factor
Associated with severe, chronic proximal tubulopathy
PMID 9606250 (opens PubMed in a new tab)How it's managed
- 1
Recognize that mesna does not protect the tubule
Mesna neutralizes acrolein in the bladder and prevents hemorrhagic cystitis, but proximal tubular enzymuria and proteinuria occur despite adequate mesna — there is no established prophylaxis against ifosfamide tubulopathy.
Tubular toxicity in every patient despite mesna; no proven pharmacologic protection · PMID 2879626 (opens PubMed in a new tab)
- 2
Cap cumulative dose, especially in young children
Because total ifosfamide dose is the dominant risk factor, weigh cumulative exposure carefully: cumulative doses ≥100 g/m² should be avoided in children, and ≥60 g/m² or age <5 years should trigger heightened caution.
Dose the only independent risk factor; ≥100 g/m² to be avoided in children · PMID 8774570 (opens PubMed in a new tab)
- 3
Surveillance for the proximal-tubule signature
Monitor serum and urine for phosphate wasting (low tubular reabsorption of phosphate), proximal RTA, glycosuria with normal blood glucose, and low-molecular-weight proteinuria (β2-microglobulin); severe β2-microglobulinuria flags those at risk of chronic damage, and toxicity can worsen over years.
β2-microglobulinuria predicts chronic nephrotoxicity; long-term surveillance needed as toxicity can be permanent/progressive · PMID 19826134 (opens PubMed in a new tab)
- 4
Supportive electrolyte and alkali replacement
There is no specific antidote; management is replacing what the tubule leaks — oral phosphate, alkali for the acidosis, and (in children with rickets) calcitriol — with attention to growth and bone health.
Chronic tubular electrolyte loss requiring oral supplementation defines the clinical burden · PMID 8625085 (opens PubMed in a new tab)
What the guidelines say
Society and consensus recommendations addressing this syndrome.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
Every citation on this page is a real, PubMed-verified reference. The teaching case is an illustrative composite, not a real patient. Medical-education content — not medical advice.